JP2015516968A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015516968A5 JP2015516968A5 JP2015504745A JP2015504745A JP2015516968A5 JP 2015516968 A5 JP2015516968 A5 JP 2015516968A5 JP 2015504745 A JP2015504745 A JP 2015504745A JP 2015504745 A JP2015504745 A JP 2015504745A JP 2015516968 A5 JP2015516968 A5 JP 2015516968A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pyran
- disease
- compound
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 65
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 50
- 125000000217 alkyl group Chemical group 0.000 claims description 45
- 150000001875 compounds Chemical class 0.000 claims description 38
- 150000003839 salts Chemical class 0.000 claims description 30
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 28
- 208000035475 disorder Diseases 0.000 claims description 28
- 201000010099 disease Diseases 0.000 claims description 22
- 208000011580 syndromic disease Diseases 0.000 claims description 22
- 239000003638 chemical reducing agent Substances 0.000 claims description 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 18
- -1 pyrazoyl Chemical group 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 17
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 16
- 229910052796 boron Inorganic materials 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 13
- 208000006673 asthma Diseases 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- VSYYQDBTLGSLRK-UHFFFAOYSA-N 4,4-dimethoxyoxan-3-one Chemical compound COC1(OC)CCOCC1=O VSYYQDBTLGSLRK-UHFFFAOYSA-N 0.000 claims description 10
- 208000008589 Obesity Diseases 0.000 claims description 10
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 10
- 235000020824 obesity Nutrition 0.000 claims description 10
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 9
- BXGOXDLHSNHTCX-LURJTMIESA-N (3s)-4,4-dimethoxyoxan-3-ol Chemical compound COC1(OC)CCOC[C@@H]1O BXGOXDLHSNHTCX-LURJTMIESA-N 0.000 claims description 8
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 8
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 8
- BXGOXDLHSNHTCX-ZCFIWIBFSA-N (3r)-4,4-dimethoxyoxan-3-ol Chemical compound COC1(OC)CCOC[C@H]1O BXGOXDLHSNHTCX-ZCFIWIBFSA-N 0.000 claims description 7
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- VMKAFJQFKBASMU-KRWDZBQOSA-N (3as)-1-methyl-3,3-diphenyl-3a,4,5,6-tetrahydropyrrolo[1,2-c][1,3,2]oxazaborole Chemical compound C([C@H]12)CCN1B(C)OC2(C=1C=CC=CC=1)C1=CC=CC=C1 VMKAFJQFKBASMU-KRWDZBQOSA-N 0.000 claims description 5
- ZJQDQFFQNQUHHT-SSDOTTSWSA-N (3r)-3,4,4-trimethoxyoxane Chemical compound CO[C@@H]1COCCC1(OC)OC ZJQDQFFQNQUHHT-SSDOTTSWSA-N 0.000 claims description 4
- ZJQDQFFQNQUHHT-ZETCQYMHSA-N (3s)-3,4,4-trimethoxyoxane Chemical compound CO[C@H]1COCCC1(OC)OC ZJQDQFFQNQUHHT-ZETCQYMHSA-N 0.000 claims description 4
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims description 4
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims description 4
- 208000002249 Diabetes Complications Diseases 0.000 claims description 4
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 4
- 206010012655 Diabetic complications Diseases 0.000 claims description 4
- 206010054044 Diabetic microangiopathy Diseases 0.000 claims description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 206010022489 Insulin Resistance Diseases 0.000 claims description 4
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 206010038910 Retinitis Diseases 0.000 claims description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 4
- 201000009961 allergic asthma Diseases 0.000 claims description 4
- KHYAFFAGZNCWPT-UHFFFAOYSA-N boron;n,n-diethylaniline Chemical compound [B].CCN(CC)C1=CC=CC=C1 KHYAFFAGZNCWPT-UHFFFAOYSA-N 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 201000009101 diabetic angiopathy Diseases 0.000 claims description 4
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 4
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 claims description 4
- 229910001873 dinitrogen Inorganic materials 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 230000014509 gene expression Effects 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 230000002018 overexpression Effects 0.000 claims description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
- 150000003890 succinate salts Chemical class 0.000 claims description 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 4
- 125000000335 thiazolyl group Chemical group 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 125000005412 pyrazyl group Chemical group 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- YMJJPBWCARDMCG-ZCFIWIBFSA-N (3r)-3-methoxyoxan-4-one Chemical compound CO[C@@H]1COCCC1=O YMJJPBWCARDMCG-ZCFIWIBFSA-N 0.000 claims description 2
- YMJJPBWCARDMCG-LURJTMIESA-N (3s)-3-methoxyoxan-4-one Chemical compound CO[C@H]1COCCC1=O YMJJPBWCARDMCG-LURJTMIESA-N 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 206010007558 Cardiac failure chronic Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 208000025962 Crush injury Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 201000010046 Dilated cardiomyopathy Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000009525 Myocarditis Diseases 0.000 claims description 2
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 2
- 206010033307 Overweight Diseases 0.000 claims description 2
- 206010036346 Posterior capsule opacification Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 2
- 206010041925 Staphylococcal infections Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 206010052568 Urticaria chronic Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 206010046851 Uveitis Diseases 0.000 claims description 2
- 206010057469 Vascular stenosis Diseases 0.000 claims description 2
- 208000002223 abdominal aortic aneurysm Diseases 0.000 claims description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 208000007474 aortic aneurysm Diseases 0.000 claims description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000024376 chronic urticaria Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 208000030533 eye disease Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000024693 gingival disease Diseases 0.000 claims description 2
- 208000007565 gingivitis Diseases 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 230000004968 inflammatory condition Effects 0.000 claims description 2
- 201000006370 kidney failure Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 230000003211 malignant effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 201000008383 nephritis Diseases 0.000 claims description 2
- 210000005036 nerve Anatomy 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 125000002971 oxazolyl group Chemical group 0.000 claims description 2
- 230000010412 perfusion Effects 0.000 claims description 2
- 208000028169 periodontal disease Diseases 0.000 claims description 2
- 201000001245 periodontitis Diseases 0.000 claims description 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 2
- 208000037803 restenosis Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 206010039083 rhinitis Diseases 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical class OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 230000009529 traumatic brain injury Effects 0.000 claims description 2
- 201000008827 tuberculosis Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 12
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 229910000085 borane Inorganic materials 0.000 description 6
- 239000002904 solvent Substances 0.000 description 4
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 3
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 150000004292 cyclic ethers Chemical class 0.000 description 3
- 239000003999 initiator Substances 0.000 description 3
- DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 3
- SCHZCUMIENIQMY-UHFFFAOYSA-N tris(trimethylsilyl)silicon Chemical compound C[Si](C)(C)[Si]([Si](C)(C)C)[Si](C)(C)C SCHZCUMIENIQMY-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical class [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- ZDQWVKDDJDIVAL-UHFFFAOYSA-N catecholborane Chemical compound C1=CC=C2O[B]OC2=C1 ZDQWVKDDJDIVAL-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261621138P | 2012-04-06 | 2012-04-06 | |
| US61/621,138 | 2012-04-06 | ||
| PCT/US2013/035396 WO2013152269A1 (en) | 2012-04-06 | 2013-04-05 | Fused cyclopentyl antagonists of ccr2 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017006578A Division JP2017095499A (ja) | 2012-04-06 | 2017-01-18 | Ｃｃｒ２の縮合シクロペンチル拮抗薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015516968A JP2015516968A (ja) | 2015-06-18 |
| JP2015516968A5 true JP2015516968A5 (https=) | 2016-06-02 |
| JP6110474B2 JP6110474B2 (ja) | 2017-04-05 |
Family
ID=48096365
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015504745A Expired - Fee Related JP6110474B2 (ja) | 2012-04-06 | 2013-04-05 | Ｃｃｒ２の縮合シクロペンチル拮抗薬 |
| JP2017006578A Pending JP2017095499A (ja) | 2012-04-06 | 2017-01-18 | Ｃｃｒ２の縮合シクロペンチル拮抗薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017006578A Pending JP2017095499A (ja) | 2012-04-06 | 2017-01-18 | Ｃｃｒ２の縮合シクロペンチル拮抗薬 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8822460B2 (https=) |
| EP (1) | EP2834234B1 (https=) |
| JP (2) | JP6110474B2 (https=) |
| CN (1) | CN104619702B (https=) |
| AU (1) | AU2013243353B2 (https=) |
| CA (1) | CA2869647A1 (https=) |
| ES (1) | ES2648175T3 (https=) |
| HK (1) | HK1210150A1 (https=) |
| WO (1) | WO2013152269A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8822460B2 (en) * | 2012-04-06 | 2014-09-02 | Janssen Pharmaceutica Nv | Fused cyclopentyl antagonists of CCR2 |
| AU2013290418B2 (en) * | 2012-07-19 | 2017-08-03 | Chaozhong Cai | Octahydro-cyclopentapyrrolyl antagonists of CCR2 |
| ES2764840T3 (es) | 2015-01-28 | 2020-06-04 | Univ Bordeaux | Uso de plerixafor para tratar y/o prevenir exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica |
| ES2904252T3 (es) * | 2015-05-21 | 2022-04-04 | Chemocentryx Inc | Moduladores de CCR2 |
| CN106366091A (zh) * | 2016-08-24 | 2017-02-01 | 河北艾林国际贸易有限公司 | 海南霉素及其衍生物的用途及其海南霉素衍生物和制备方法 |
| CN118267479A (zh) | 2017-09-25 | 2024-07-02 | 凯莫森特里克斯股份有限公司 | 使用趋化因子受体2(ccr2)拮抗剂和pd-1/pd-l1抑制剂的联合治疗 |
| US20190269664A1 (en) | 2018-01-08 | 2019-09-05 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
| IL275898B2 (en) | 2018-01-08 | 2025-05-01 | Chemocentryx Inc | Methods for treating solid tumors with CCR2 antagonists |
| EP3833762A4 (en) | 2018-08-09 | 2022-09-28 | Verseau Therapeutics, Inc. | Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof |
| CN110028469B (zh) * | 2019-04-28 | 2022-08-09 | 南京药石科技股份有限公司 | 一种非阿片类镇痛药的关键中间体的制备方法及应用 |
| TW202300150A (zh) | 2021-03-18 | 2023-01-01 | 美商薛定諤公司 | 環狀化合物及其使用方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU683287B2 (en) * | 1993-07-23 | 1997-11-06 | Merrell Pharmaceuticals Inc. | Novel 9-N-bicyclic nucleoside agents useful as selective inhibitors of proinflammatory cytokines |
| IL133680A0 (en) | 1999-09-10 | 2001-04-30 | Can Fite Technologies Ltd | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
| MY129850A (en) | 2002-04-29 | 2007-05-31 | Merck Sharp & Dohme | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
| EP1501507B1 (en) * | 2002-04-29 | 2008-05-28 | Merck & Co., Inc. | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
| AR045875A1 (es) * | 2003-10-27 | 2005-11-16 | Merck & Co Inc | Procedimiento para la preparacion del antagonista ccr-2 |
| US7381738B2 (en) | 2004-02-19 | 2008-06-03 | Bristol-Myers Squibb Company | Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity |
| CN1972913A (zh) | 2004-04-26 | 2007-05-30 | 默克公司 | 四氢吡喃基环戊基四氢吡啶并吡啶趋化因子受体活性调节剂 |
| WO2005105092A2 (en) * | 2004-04-28 | 2005-11-10 | Merck & Co., Inc. | 3,3-disubstituted tetrahydropyranyl cyclopentyl amide modulators of chemokine receptor activity |
| US20070270417A1 (en) | 2004-07-22 | 2007-11-22 | Glaxo Group Limited | Antibacterial Agents |
| EP1861386A1 (en) * | 2005-03-11 | 2007-12-05 | Merck & Co., Inc. | Process for the preparation of (r)-4,4-dialkoxy-pyran-3-ols such as (r)-4,4-dimethoxy-pyran-3-ol |
| WO2009033281A1 (en) | 2007-09-14 | 2009-03-19 | Methylgene Inc. | Cancer combination therapy with a selective inhibitor of histone deacetylase hdac1, hdac2 and/or hdac3 and a microtubule stabilizer |
| MX2010003113A (es) * | 2007-09-25 | 2010-04-01 | Abbott Lab | Compuestos de octahidropentaleno como antagonistas del receptor de quimiocina. |
| US8822460B2 (en) * | 2012-04-06 | 2014-09-02 | Janssen Pharmaceutica Nv | Fused cyclopentyl antagonists of CCR2 |
-
2013
- 2013-04-04 US US13/856,666 patent/US8822460B2/en not_active Expired - Fee Related
- 2013-04-05 CA CA2869647A patent/CA2869647A1/en not_active Abandoned
- 2013-04-05 JP JP2015504745A patent/JP6110474B2/ja not_active Expired - Fee Related
- 2013-04-05 WO PCT/US2013/035396 patent/WO2013152269A1/en not_active Ceased
- 2013-04-05 HK HK15110873.4A patent/HK1210150A1/xx unknown
- 2013-04-05 CN CN201380029978.4A patent/CN104619702B/zh not_active Expired - Fee Related
- 2013-04-05 AU AU2013243353A patent/AU2013243353B2/en not_active Ceased
- 2013-04-05 EP EP13716709.4A patent/EP2834234B1/en not_active Not-in-force
- 2013-04-05 ES ES13716709.4T patent/ES2648175T3/es active Active
-
2014
- 2014-07-24 US US14/339,918 patent/US9150532B2/en not_active Expired - Fee Related
-
2017
- 2017-01-18 JP JP2017006578A patent/JP2017095499A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015516968A5 (https=) | ||
| AU2018236691B2 (en) | N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | |
| JP2005519028A5 (https=) | ||
| US9309224B2 (en) | N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | |
| JP5411927B2 (ja) | Ｃｃｒ１アンタゴニストとしてのピラゾール化合物 | |
| JP6254075B2 (ja) | カリウムチャネル遮断剤としてのアミン誘導体 | |
| CA2457444A1 (en) | 1h-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1- antagonistic activity | |
| JP2021530565A5 (https=) | ||
| JP2021501151A5 (https=) | ||
| WO2003041707A1 (en) | N-adamantylmethyl derivates and intermediates as pharmaceutical compositions and processes for their preparation | |
| JP7134178B2 (ja) | カルシウムチャネル阻害剤 | |
| AU2002347741A1 (en) | N-adamantylmethyl derivates and intermediates as pharmaceutical compositions and processes for their preparation | |
| US12454516B2 (en) | Nitric oxide releasing prodrugs of MDA and MDMA | |
| JP2012524107A5 (https=) | ||
| JP4575918B2 (ja) | ４−アリル−ニコチンアミド誘導体の製造方法 | |
| MX2010013058A (es) | Derivado de benceno o tiofeno y su uso como inhibidor de proteina 1 de adhesion vascular. | |
| JP5727482B2 (ja) | 神経刺激性ピペラジンの合成 | |
| JPWO2010107115A1 (ja) | グリシントランスポーター阻害物質 | |
| TW202304421A (zh) | 整合應激路徑之調節劑 | |
| AU2021229414A1 (en) | Synthesis of novel EP4 antagonist and use in cancers and inflammations | |
| TWI725098B (zh) | 藉由使用極性非質子性溶劑掌性解析n-[4-(1-胺基乙基)-苯基]-磺醯胺衍生物之方法 | |
| JP7746266B2 (ja) | 新規ピロール化合物 | |
| JP5642149B2 (ja) | ヒスタミンｈ３受容体モジュレーターの調製プロセス | |
| JP7168456B2 (ja) | インドリン誘導体およびそれらを使用するならびに生産する方法 | |
| JP6569678B2 (ja) | ２−アミノチアゾール誘導体またはその塩 |